EUVIMEDEUVIMED entdecken
Crossref

Synthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker

Xuran Zhang, Choong Mo Kang, Joon Young Choi, Yearn Seong Choe iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Xuran Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea. Hauptthemen laut MEDLINE: Triazines, Radiopharmaceuticals, Membrane Proteins, Gelatinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dimeric fibroblast activation protein inhibitor (FAPI) radioligands are promising candidates for theranostic applications because of their enhanced tumor uptake and prolonged retention compared to monomeric radioligands. Several linker strategies have been investigated to connect two FAPI motifs and a radiometal chelator in a dimer design. In this study, we report the development of a novel dimeric FAPI radioligand, [68Ga]Ga-1, which utilizes a triazine core as a trifunctional linker. The ligand [natGa/68Ga]Ga-1 was synthesized by chelating gallium or gallium-68 to 2-(DOTAGA-NH-ethyl-NH)-4,6-bis(Gly-FAPI)-1,3,5-triazine (1). [natGa]Ga-1, a nonradioactive ligand, exhibited FAP-binding affinity comparable to that of FAPI-04 (IC50 = 2.42 nM vs 1.57 nM). [68Ga]Ga-1 was synthesized in high decay-corrected radiochemical yields (91.7-94.7%) with high molar activities (40.8-50.0 GBq/μmol) and showed good stability in phosphate-buffered saline and fetal bovine serum. In vitro studies confirmed FAP-specific cellular uptake of [68Ga]Ga-1. Positron emission tomography (PET) imaging and ex vivo biodistribution of [68Ga]Ga-1 in U87MG tumor-bearing mice demonstrated high tumor uptake and retention, which were significantly blocked by FAPI-04, confirming FAP specificity. Notably, [68Ga]Ga-1 demonstrated superior and more sustained tumor uptake than monomeric [68Ga]Ga-FAPI-04, indicating improved pharmacokinetics. Altogether, the triazine linker is well suited for constructing dimeric FAPI radioligands, and [68Ga]Ga-1 holds potential as a FAP-targeted radioligand for theranostic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazinesRadiopharmaceuticalsMembrane ProteinsGelatinasesAnimalsGallium RadioisotopesMiceHumansTissue DistributionCell Line, TumorPositron-Emission TomographyFemaleMice, NudeLigandsSerine EndopeptidasesEndopeptidasesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

DOTAGAFAP inhibitor (FAPI)PETdimerfibroblast activation protein (FAP)gallium-68triazine

Substanzen

TriazinesGallium RadioisotopesRadiopharmaceuticalsMembrane ProteinsGelatinasesLigandsSerine EndopeptidasesEndopeptidasesFibroblast Activation Protein AlphaGallium-68

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.

ORCID-Profile: Yearn Seong Choe

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Zhang, X., Kang, C. M., Choi, J. Y., & Choe, Y. S. (2025). Synthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00979

Vancouver

Zhang X, Kang CM, Choi JY, Choe YS. Synthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00979

BibTeX
@article{Zhang2025,
  author = {Zhang, Xuran and Kang, Choong Mo and Choi, Joon Young and Choe, Yearn Seong},
  title = {Synthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00979}
}
Kostenlos starten →